Group 1 - The major shareholder and chairman of Kangchen Pharmaceutical has continuously increased his stake, acquiring a total of 278,000 shares at an average price of HKD 11.34, indicating confidence in the company's future development [1] - Since June 16, Kangchen Pharmaceutical has repurchased shares 15 times, totaling 4.795 million shares and an expenditure of HKD 53.8248 million, reflecting the company's commitment to returning value to shareholders [3] - The company's core product, Uremic Granules, is the only "strongly recommended" medication listed in the clinical application guidelines for chronic kidney disease, showcasing its leading position in the kidney disease sector [6] Group 2 - Kangchen Pharmaceutical is actively expanding its product portfolio beyond kidney disease, venturing into six additional fields, establishing a "1+6" product structure to enhance its market presence [6][7] - The company has a clear strategic focus on innovation, with a pipeline that includes both traditional Chinese medicine and innovative drugs, prioritizing the kidney and imaging sectors [7] - Despite recent stock price increases, Kangchen Pharmaceutical's price-to-earnings (PE) ratio remains around 10 times, suggesting that its innovative value is yet to be fully realized [8]
大股东增持叠加持续回购，康臣药业(01681)迎关键配置窗口期